


What is claimed is:

1. A compound according to Formula (I):



5

wherein,

R1 is selected from the group consisting of C<sub>1</sub>-C<sub>9</sub>alkyl, C<sub>1-2</sub>alkylAr, and Ar;

R2 is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>9</sub>alkyl, C<sub>1-4</sub>alkylAr',

- 10 NR<sub>4</sub>, NC(O)R<sub>4</sub>, C<sub>2-4</sub>alkylNR<sub>3</sub>R<sub>4</sub>, C<sub>1-3</sub>alkylC(O)NR<sub>3</sub>R<sub>4</sub>, C<sub>1-3</sub>alkylC(O)Ar', C<sub>2-3</sub>alkylNHC(O)NR<sub>3</sub>R<sub>4</sub>, C<sub>2-3</sub>alkylNHC(O)Ar', and C<sub>1-2</sub>alkylSO<sub>2</sub>R<sub>4</sub>;

R3 is selected from the group consisting of C<sub>1</sub>-C<sub>9</sub>alkyl, C<sub>1-2</sub>alkylAr, and Ar;

R4 is R3, Ar', or R4 may be taken together with R3 and the nitrogen atom to which they are attached to form a heterocyclic ring which is optionally substituted with one,

- 15 two, or three substituents selected from the group consisting of C<sub>1-3</sub>alkyl, aryl, C<sub>1-3</sub>alkoxy (optionally substituted by one to three F), aryloxy, carboxy, oxo, hydroxy, amino, nitro, and cyano, or which may be optionally fused to an aryl, a heteroaryl, or a second heterocyclic ring;

Ar is selected from the group consisting of phenyl, furyl, and thienyl, all of which

- 20 can be optionally substituted with one, two, or three substituents selected from the group consisting of: C<sub>1</sub>-C<sub>3</sub>alkyl, CN, F, Cl, Br, and I;

Ar' is selected from the group consisting of: phenyl, naphthyl, furyl, pyridyl, thienyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, benzofuranyl, indolyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl,

- 25 and pyrimidyl, all of which can be optionally substituted with one, two, or three substituents from the group consisting of: C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, (CH<sub>2</sub>)<sub>0-5</sub>CO<sub>2</sub>R<sub>1</sub>, C(O)N(R<sub>1</sub>)<sub>2</sub>, CN, (CH<sub>2</sub>)<sub>0-5</sub>OH, NO<sub>2</sub>, F, Cl, Br, I, CF<sub>3</sub>, N(R<sub>1</sub>)<sub>2</sub>, and NHC(O)R<sub>1</sub>;

A is selected from the group of C(O)NHOH or N(CHO)OH;

- 30 X is NH, when Y is C(O), or X is CH<sub>2</sub> when Y is C(O) or CH<sub>2</sub>.

2. A compound according to claim 1 selected from the group consisting of:

- N-[(S)-1-Benzyl-4-pentyl-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;
- N-[(S)-1,4-Dibenzyl-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;
- N-[(S)-1-Benzyl-4-butyl-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;
- 5 N-[(S)-2,5-Dioxo-4-pentyl-1-phenyl-imidazolidin-4-ylmethyl]-N-hydroxyformamide;
- N-[(S)-4-Butyl-1-(3,4-dichloro-benzyl)-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;
- N-[(S)-4-Butyl-2,5-dioxo-1-(2-oxo-2-phenyl-ethyl)-imidazolidin-4-ylmethyl]-N-
- 10 hydroxyformamide;
- N-[(S)-1-Biphenyl-4-ylmethyl-4-butyl-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;
- N-[(S)-1-Benzyl-4-cyclohexylmethyl-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;
- 15 N-[(S)-4-Butyl-1-[2-(5-chloro-3-methyl-1-benzo[b]thiophen-2-yl)-2-oxo-ethyl]-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;
- 2-[(S)-4-Butyl-4-[(formyl-hydroxy-amino)methyl]-2,5-dioxo-imidazolidin-1-yl]-N-(3,5-dichlorophenyl)acetamide;
- 2-[(S)-4-Butyl-4-[(formylhydroxyamino)methyl]-2,5-dioxo-
- 20 imidazolidin-1-ylmethyl}benzoic acid methyl ester;
- N-[(S)-4-Butyl-1-(2-morpholin-4-yl-ethyl)-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;
- N-[(S)-1-(2-Benzofuran-2-yl-2-oxo-ethyl)-4-butyl-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide; and
- 25 2-[(S)-4-Butyl-4-[(formylhydroxyamino)methyl]-2,5-dioxo-imidazolidin-1-ylmethyl}benzoic acid;
- or a pharmaceutically acceptable salt thereof.

3. A method of treating a bacterial infection by administering to a subject in
- 30 need of treatment a compound according to claim 1.